Perindopril erbumine

Cat. No.: HY-B0130A
CAS No.: 107133-36-8
Molecular Formula: C₃₃H₄₃N₃O₅
Molecular Weight: 441.6
Target: Angiotensin-converting Enzyme (ACE)
Pathway: Metabolic Enzyme/Protease
Storage:
- Powder: -20°C for 3 years, 4°C for 2 years
- In solvent: -80°C for 6 months, -20°C for 1 month

SOLVENT & SOLUBILITY

In Vitro

H₂O : ≥ 50 mg/mL (113.22 mM)
DMSO : 10 mg/mL (22.64 mM; Need ultrasonic)

* “≥” means soluble, but saturation unknown.

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent</th>
<th>Mass</th>
<th>Solubility</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>2.2645 mL</td>
<td>11.3225 mL</td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.4529 mL</td>
<td>2.2645 mL</td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.2264 mL</td>
<td>1.1322 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description
Perindopril erbumine (Perindopril tert-butylamine salt) is a potent ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease. Target: ACE
Perindopril is a long-acting ACE inhibitor. It is used to treat high blood pressure, heart failure or stable coronary artery disease in form of perindopril arginine (trade names include Coversyl, Coversum) or perindopril erbumine (trade name Aceon). According to the Australian government's Pharmaceutical Benefits Scheme website, based on data provided to the Australian Department of Health and Aging by the manufacturer, perindopril arginine and perindopril erbumine are therapeutically equivalent and may be interchanged without differences in clinical effect. However the dose prescribed to achieve the same effect will differ due to different molecular weights for the two forms. Perindopril is one of the most prescribed inhibitors of angiotensin converting enzyme, has a large evidence base, which allows to use it in patients with hypertension, diabetes mellitus type 2, coronary heart disease and chronic heart failure. In this review, the author focused on the evidence of organoprotecting properties of perindopril that lie outside lowering blood pressure.
REFERENCES
